pioglitazone has been researched along with Hypertension in 92 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| " A total of 522 patients with hypertension and/or dyslipidemia who had one or more silent cerebral infarcts, advanced carotid atherosclerosis or microalbuminuria at baseline were randomly treated with (n=254) or without pioglitazone (n=268) and observed for a medium of 672 days." | 9.19 | Effects of pioglitazone on macrovascular events in patients with type 2 diabetes mellitus at high risk of stroke: the PROFIT-J study. ( Kawamori, R; Kitagawa, K; Kitakaze, M; Matsuhisa, M; Matsumoto, M; Onuma, T; Watada, H; Yamasaki, Y; Yamazaki, T; Yoshii, H, 2014) |
| "To evaluate the efficacy and safety of combination therapy with candesartan cilexetil (CC) and pioglitazone hydrochloride (PIO) in patients with hypertension and type 2 diabetes mellitus." | 9.15 | Efficacy and safety of combination therapy with candesartan cilexetil and pioglitazone hydrochloride in patients with hypertension and type 2 diabetes mellitus. ( Enya, K; Kaku, K; Sugiura, K; Totsuka, N, 2011) |
| "The combination of pioglitazone and RAS-Is showed therapeutic benefit in the reduction of urinary albumin excretion for type 2 diabetic patients with hypertension and microalbuminuria." | 9.15 | Pioglitazone reduces urinary albumin excretion in renin-angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study. ( Haneda, M; Ishizeki, K; Itoh, H; Iwashima, Y; Miura, T; Morikawa, A; Muto, E; Oshima, E; Sekiguchi, M; Yokoyama, H, 2011) |
| "Insulin sensitivity indices (SI indices) were obtained by analyzing fasting glucose and insulin concentration with homeostasis model assessment (HOMA), the glucose and insulin profiles after 75 g dextrose oral glucose tolerance tests (OGTT, Matsuda-Index) and euglycemic hyperinsulinemic clamp (m-value) in a double-blind placebo-controlled study in 60 patients with arterial hypertension before and after 4 months treatment with Pioglitazone 45 mg (PIO45)." | 9.14 | Impact of insulin sensitivity treatment with pioglitazone on endothelial function in non-diabetic patients with arterial hypertension. ( Bär, F; Franke, S; Konrad, T; Schneider, F; Vossler, S, 2009) |
| " In this study, we evaluated the clinical efficacy of pioglitazone in the treatment of diabetic patients with hypertension undergoing hemodialysis (HD)." | 9.13 | Clinical investigation of the effects of pioglitazone on the improvement of insulin resistance and blood pressure in type 2-diabetic patients undergoing hemodialysis. ( Abe, M; Kikuchi, F; Matsumoto, K; Okada, K, 2008) |
| " This work examines the effect of pioglitazone on 24-hour ambulatory BP monitoring in patients with type 2 diabetes and difficult-to-control hypertension." | 9.12 | Pioglitazone decreases ambulatory blood pressure in type 2 diabetics with difficult-to-control hypertension. ( de Rivas, B; Fernández, C; Fernández-Cruz, A; Luque, M; Martell, N, 2007) |
| "The present findings demonstrate that pioglitazone improves endothelial function in nondiabetic hypertensive individuals with insulin resistance, and that the improvement is associated with the amelioration of insulin resistance itself rather than that of hyperglycemia or hyperinsulinemia." | 9.11 | Pioglitazone-induced insulin sensitization improves vascular endothelial function in nondiabetic patients with essential hypertension. ( Hiuge, A; Horio, T; Kawano, Y; Suzuki, K; Suzuki, M; Takamisawa, I; Yoshimasa, Y, 2005) |
| "The present findings demonstrate that pioglitazone improves LV diastolic function without LV mass regression in hypertensive patients in proportion to the amelioration of insulin resistance." | 9.11 | Pioglitazone improves left ventricular diastolic function in patients with essential hypertension. ( Funahashi, T; Hiuge, A; Horio, T; Iwashima, Y; Kamide, K; Kawano, Y; Kihara, S; Suzuki, K; Suzuki, M; Takamisawa, I; Takiuchi, S; Yoshimasa, Y, 2005) |
| "The oral antidiabetic agent pioglitazone improves insulin sensitivity and glycemic control and appears to lower atherogenic dense LDL in type 2 diabetes." | 9.10 | Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. ( Baumstark, MW; Destani, R; Friedrich, I; Füllert, S; Konrad, T; Krebs, K; März, W; Wieland, H; Winkler, K, 2003) |
| "Our study aimed to investigate the effect of pioglitazone (PIO) on the obesity-associated metabolic effects and whether this effect is associated with modulation of catechol O-methyl transferase (COMT) expression in the high fat diet (HFD) induced obese rats." | 7.96 | Pioglitazone ameliorates high fat diet-induced hypertension and induces catechol o-methyl transferase expression in rats. ( Abd Elaziz, AI; Abulsoud, AI; El-Shafey, M; Elsadek, BEM; Hegazy, M; Salama, SA, 2020) |
| " We report a case of 55-year-old man with primary aldosteronism (PA) whose hyperaldosteronism was suppressed with the PPAR γ agonist pioglitazone." | 7.79 | Suppression of primary aldosteronism and resistant hypertension by the peroxisome proliferator-activated receptor gamma agonist pioglitazone. ( Harada, E; Kashiwagi, Y; Mizuno, Y; Morita, S; Shono, M; Yano, M; Yasue, H; Yoshimura, M, 2013) |
| " Here, we hypothesized that pioglitazone protects against the hypertension and related vascular derangements caused by the immunosuppressant drug cyclosporine (CSA)." | 7.77 | Pioglitazone abrogates cyclosporine-evoked hypertension via rectifying abnormalities in vascular endothelial function. ( Abd-Elrahman, KS; Abdel-Galil, AG; Abdel-Rahman, AA; El-Gowelli, HM; El-Mas, MM; Saad, EI, 2011) |
| "Here we investigated cinnamaldehyde (CA) effect on diabetes-induced hypertension." | 7.77 | Cinnamaldehyde protects from the hypertension associated with diabetes. ( Badawy, D; El-Bassossy, HM; Fahmy, A, 2011) |
| " Pioglitazone treatment (3 mg/kg body weight/d for 6 weeks), a peroxisome proliferator-activated receptor γ agonist, reversibly improved atherogenic dyslipidemia and insulin resistance and fully restored flow-mediated dilation with persistent benefits." | 7.77 | Rhesus macaques develop metabolic syndrome with reversible vascular dysfunction responsive to pioglitazone. ( Cheng, H; Ding, Y; Han, C; Hou, N; Huang, PL; Li, C; Li, K; Liu, N; Liu, Y; Mao, J; Raab, S; Sebokova, E; Shang, S; Song, Z; Wang, H; Wang, J; Xue, L; Zhang, H; Zhang, R; Zhang, X; Zhang, Y; Zheng, W; Zhu, T, 2011) |
| "Very recent subgroup analysis from the PROspective pioglitAzone Clinical Trial In macroVascular Events has shown that pioglitazone reduces the risk of recurrent stroke in type 2 diabetic patients." | 7.74 | Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure. ( Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Nakamura, T; Ogawa, H; Tokutomi, Y; Yamamoto, E; Yamashita, T, 2007) |
| " We have studied the effects of pioglitazone and rosiglitazone on the endothelial ability to counteract vascular smooth muscle contractility in genetic hypertension." | 7.74 | Effects of pioglitazone and rosiglitazone on aortic vascular function in rat genetic hypertension. ( Llorens, S; Mendizabal, Y; Nava, E, 2007) |
| "Long-term administration of pioglitazone attenuated left ventricular hypertrophy and fibrosis as well as inhibited phosphorylation of mammalian target of rapamycin and p70S6 kinase in the heart of hypertensive rats." | 7.74 | Pioglitazone attenuates cardiac hypertrophy in rats with salt-sensitive hypertension: role of activation of AMP-activated protein kinase and inhibition of Akt. ( Cheng, XW; Kato, MF; Koike, Y; Miyachi, M; Murate, T; Murohara, T; Nagata, K; Nishizawa, T; Noda, A; Obata, K; Shibata, R; Tsuboi, K; Yamada, T; Yazawa, H; Yokota, M, 2008) |
| "The present study investigates the effect of pioglitazone treatment on blood pressure, vascular reactivity and antioxidant enzymes in L-NAME induced hypertension in normal and STZ-diabetic rats." | 7.73 | Effect of pioglitazone on L-NAME induced hypertension in diabetic rats. ( Balaraman, R; Majithiya, JB; Parmar, AN; Trivedi, CJ, 2005) |
| "We investigated the long-term effects of the thiazolidinedione PPARgamma activator pioglitazone on cardiac inflammation in stroke-prone spontaneously hypertensive rats (SHRSP), a model of malignant of hypertension." | 7.72 | Long-term effects of the PPAR gamma activator pioglitazone on cardiac inflammation in stroke-prone spontaneously hypertensive rats. ( Amiri, F; Benkirane, K; Diep, QN; Paradis, P; Schiffrin, EL, 2004) |
| " This study was undertaken to examine the in vivo effects of the thiazolidine compound pioglitazone (PIO) on carotid neointimal thickening, after endothelial injury in Wistar rats and vascular hypertrophy in stroke-prone spontaneously hypertensive rats (SHR-SP/Izm)." | 7.70 | Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy. ( Demura, H; Irie, K; Muraki, T; Naruse, K; Naruse, M; Shizume, H; Tago, K; Tanabe, A; Tanaka, M; Yoshimoto, T; Zardi, L, 1999) |
| "Hypertension is often associated with insulin resistance, dyslipidemia and obesity, which indicate a prediabetic state and increased risk of cardiovascular disease." | 6.70 | Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. ( Badenhoop, K; Füllert, S; Haak, E; Konrad, T; Lübben, G; Rau, H; Schneider, F; Usadel, KH, 2002) |
| "Metabolic syndrome is considered as clustering of cardiovascular risk factors related to insulin resistance." | 6.44 | [Pioglitazone effects on blood pressure in patients with metabolic syndrome]. ( Kushiro, T; Takahashi, A, 2008) |
| "Pioglitazone was also associated with reduced recurrent IS in patients who also used telmisartan (p for interaction = 0." | 5.56 | Pioglitazone and PPAR-γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study. ( Lee, TH; Li, YR; Lin, YS; Liu, CH; Sung, PS; Wei, YC, 2020) |
| "Biochemical markers of NAFLD worsened over time." | 5.40 | Resistant nonalcoholic fatty liver disease amelioration with rosuvastatin and pioglitazone combination therapy in a patient with metabolic syndrome. ( Black, CA; Fleming, JW; Malinowski, SS; Miller, KH; Riche, DM; Wofford, MR, 2014) |
| "Pioglitazone treatment (2." | 5.38 | Reduction of renal lipid content and proteinuria by a PPAR-γ agonist in a rat model of angiotensin II-induced hypertension. ( Hongo, M; Ishizaka, N; Nagai, R; Saito, K; Sakamoto, A, 2012) |
| "Pioglitazone treatment increased PPARgamma expression and activity in OP rats, suggesting a possible direct ligand-related effect of pioglitazone." | 5.32 | Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity. ( Dobrian, AD; Khraibi, AA; Prewitt, RL; Schriver, SD, 2004) |
| "When pioglitazone was administered to the rats at a dose of 10 mg/kg/day for 4 weeks from 12 weeks of age, plasma triglyceride and insulin levels and systolic blood pressure decreased, and blood glucose reduction in response to insulin was normalized." | 5.30 | Effect of an insulin sensitizer, pioglitazone, on hypertension in fructose-drinking rats. ( Ikeda, H; Nomura, C; Odaka, H; Suzuki, M, 1997) |
| "Hypertension is frequently associated with insulin resistance." | 5.29 | Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. ( Boegehold, MA; Dubey, RK; Kotchen, TA; Reddy, SR; Zhang, HY, 1993) |
| "Pioglitazone treatment prevented the development of hypertension and reduced plasma insulin concentration by 70% and 37% in rats fed a high-fat or glucose diet, respectively (P < ." | 5.29 | Pioglitazone attenuates diet-induced hypertension in rats. ( DeGrange, LM; Kaufman, LN; Peterson, MM, 1995) |
| "In non-diabetic patients with hypertension or hypercholesterolemia, pioglitazone improves insulin sensitivity, lipid profile, and inflammation but does not affect endothelin activity." | 5.19 | PPARγ activation does not affect endothelin activity in non-diabetic patients with hypertension or hypercholesterolemia. ( Campia, U; Cardillo, C; Matuskey, LA; Panza, JA; Tesauro, M, 2014) |
| " A total of 522 patients with hypertension and/or dyslipidemia who had one or more silent cerebral infarcts, advanced carotid atherosclerosis or microalbuminuria at baseline were randomly treated with (n=254) or without pioglitazone (n=268) and observed for a medium of 672 days." | 5.19 | Effects of pioglitazone on macrovascular events in patients with type 2 diabetes mellitus at high risk of stroke: the PROFIT-J study. ( Kawamori, R; Kitagawa, K; Kitakaze, M; Matsuhisa, M; Matsumoto, M; Onuma, T; Watada, H; Yamasaki, Y; Yamazaki, T; Yoshii, H, 2014) |
| "The combination of pioglitazone and RAS-Is showed therapeutic benefit in the reduction of urinary albumin excretion for type 2 diabetic patients with hypertension and microalbuminuria." | 5.15 | Pioglitazone reduces urinary albumin excretion in renin-angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study. ( Haneda, M; Ishizeki, K; Itoh, H; Iwashima, Y; Miura, T; Morikawa, A; Muto, E; Oshima, E; Sekiguchi, M; Yokoyama, H, 2011) |
| "To evaluate the efficacy and safety of combination therapy with candesartan cilexetil (CC) and pioglitazone hydrochloride (PIO) in patients with hypertension and type 2 diabetes mellitus." | 5.15 | Efficacy and safety of combination therapy with candesartan cilexetil and pioglitazone hydrochloride in patients with hypertension and type 2 diabetes mellitus. ( Enya, K; Kaku, K; Sugiura, K; Totsuka, N, 2011) |
| "Insulin sensitivity indices (SI indices) were obtained by analyzing fasting glucose and insulin concentration with homeostasis model assessment (HOMA), the glucose and insulin profiles after 75 g dextrose oral glucose tolerance tests (OGTT, Matsuda-Index) and euglycemic hyperinsulinemic clamp (m-value) in a double-blind placebo-controlled study in 60 patients with arterial hypertension before and after 4 months treatment with Pioglitazone 45 mg (PIO45)." | 5.14 | Impact of insulin sensitivity treatment with pioglitazone on endothelial function in non-diabetic patients with arterial hypertension. ( Bär, F; Franke, S; Konrad, T; Schneider, F; Vossler, S, 2009) |
| "Pioglitazone was associated with a rapid increase in body weight and an increase in diurnal proximal sodium reabsorption, without any change in renal haemodynamics or in the modulation of the renin-angiotensin aldosterone system to changes in salt intake." | 5.14 | Effects of the peroxisome proliferator-activated receptor (PPAR)-gamma agonist pioglitazone on renal and hormonal responses to salt in diabetic and hypertensive individuals. ( Burnier, M; Deleaval, P; Jornayvaz, FR; Maillard, M; Nussberger, J; Pechere-Bertschi, A; Vinciguerra, M; Zanchi, A, 2010) |
| " In this study, we evaluated the clinical efficacy of pioglitazone in the treatment of diabetic patients with hypertension undergoing hemodialysis (HD)." | 5.13 | Clinical investigation of the effects of pioglitazone on the improvement of insulin resistance and blood pressure in type 2-diabetic patients undergoing hemodialysis. ( Abe, M; Kikuchi, F; Matsumoto, K; Okada, K, 2008) |
| " This work examines the effect of pioglitazone on 24-hour ambulatory BP monitoring in patients with type 2 diabetes and difficult-to-control hypertension." | 5.12 | Pioglitazone decreases ambulatory blood pressure in type 2 diabetics with difficult-to-control hypertension. ( de Rivas, B; Fernández, C; Fernández-Cruz, A; Luque, M; Martell, N, 2007) |
| "The present findings demonstrate that pioglitazone improves endothelial function in nondiabetic hypertensive individuals with insulin resistance, and that the improvement is associated with the amelioration of insulin resistance itself rather than that of hyperglycemia or hyperinsulinemia." | 5.11 | Pioglitazone-induced insulin sensitization improves vascular endothelial function in nondiabetic patients with essential hypertension. ( Hiuge, A; Horio, T; Kawano, Y; Suzuki, K; Suzuki, M; Takamisawa, I; Yoshimasa, Y, 2005) |
| "The present findings demonstrate that pioglitazone improves LV diastolic function without LV mass regression in hypertensive patients in proportion to the amelioration of insulin resistance." | 5.11 | Pioglitazone improves left ventricular diastolic function in patients with essential hypertension. ( Funahashi, T; Hiuge, A; Horio, T; Iwashima, Y; Kamide, K; Kawano, Y; Kihara, S; Suzuki, K; Suzuki, M; Takamisawa, I; Takiuchi, S; Yoshimasa, Y, 2005) |
| "The oral antidiabetic agent pioglitazone improves insulin sensitivity and glycemic control and appears to lower atherogenic dense LDL in type 2 diabetes." | 5.10 | Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. ( Baumstark, MW; Destani, R; Friedrich, I; Füllert, S; Konrad, T; Krebs, K; März, W; Wieland, H; Winkler, K, 2003) |
| " These include new evidence about nutrition, antiplatelet therapy, anticoagulation, lipid-lowering therapy, hypertension control, pioglitazone, and carotid endarterectomy and stenting." | 5.05 | Recent advances in preventing recurrent stroke. ( Spence, JD, 2020) |
| "Our study aimed to investigate the effect of pioglitazone (PIO) on the obesity-associated metabolic effects and whether this effect is associated with modulation of catechol O-methyl transferase (COMT) expression in the high fat diet (HFD) induced obese rats." | 3.96 | Pioglitazone ameliorates high fat diet-induced hypertension and induces catechol o-methyl transferase expression in rats. ( Abd Elaziz, AI; Abulsoud, AI; El-Shafey, M; Elsadek, BEM; Hegazy, M; Salama, SA, 2020) |
| "Catechol-O-methyltransferase (COMT) metabolizes 2-hydroxyestradiol into 2-methoxyestradiol (2-ME); COMT deficiency has shown to be associated with hypertension in men and preeclampsia, the disease associated with hypersensitivity of pressor response against angiotensin II (Ang II)." | 3.85 | Catechol-O-Methyltransferase Deficiency Leads to Hypersensitivity of the Pressor Response Against Angiotensin II. ( Kanasaki, K; Kanasaki, M; Koya, D; Takeda, S; Ueki, N, 2017) |
| "Pioglitazone treatment suppressed excess lipid accumulation and superoxide production in the aorta in an angiotensin II-induced rat model of hypertension." | 3.81 | Pioglitazone Reduces Vascular Lipid Accumulation in Angiotensin II-Induced Hypertensive Rat. ( Higashikuni, Y; Hongo, M; Imai, Y; Ishizaka, N; Koike, K; Komuro, I; Nagai, R; Sakamoto, A, 2015) |
| " We report a case of 55-year-old man with primary aldosteronism (PA) whose hyperaldosteronism was suppressed with the PPAR γ agonist pioglitazone." | 3.79 | Suppression of primary aldosteronism and resistant hypertension by the peroxisome proliferator-activated receptor gamma agonist pioglitazone. ( Harada, E; Kashiwagi, Y; Mizuno, Y; Morita, S; Shono, M; Yano, M; Yasue, H; Yoshimura, M, 2013) |
| " Pioglitazone treatment (3 mg/kg body weight/d for 6 weeks), a peroxisome proliferator-activated receptor γ agonist, reversibly improved atherogenic dyslipidemia and insulin resistance and fully restored flow-mediated dilation with persistent benefits." | 3.77 | Rhesus macaques develop metabolic syndrome with reversible vascular dysfunction responsive to pioglitazone. ( Cheng, H; Ding, Y; Han, C; Hou, N; Huang, PL; Li, C; Li, K; Liu, N; Liu, Y; Mao, J; Raab, S; Sebokova, E; Shang, S; Song, Z; Wang, H; Wang, J; Xue, L; Zhang, H; Zhang, R; Zhang, X; Zhang, Y; Zheng, W; Zhu, T, 2011) |
| " In this study, thirteen-week-old spontaneously hypertensive (SHR)/NDmcr-cp rats, representing a genetic model of metabolic syndrome, were treated daily with placebo, irbesartan (30 mg/kg), valsartan (10 mg/kg), or pioglitazone (10 mg/kg) for 4 weeks." | 3.77 | Irbesartan prevents metabolic syndrome in rats via activation of peroxisome proliferator-activated receptor γ. ( Jin, D; Miyazaki, M; Takai, S, 2011) |
| "Here we investigated cinnamaldehyde (CA) effect on diabetes-induced hypertension." | 3.77 | Cinnamaldehyde protects from the hypertension associated with diabetes. ( Badawy, D; El-Bassossy, HM; Fahmy, A, 2011) |
| " Here, we hypothesized that pioglitazone protects against the hypertension and related vascular derangements caused by the immunosuppressant drug cyclosporine (CSA)." | 3.77 | Pioglitazone abrogates cyclosporine-evoked hypertension via rectifying abnormalities in vascular endothelial function. ( Abd-Elrahman, KS; Abdel-Galil, AG; Abdel-Rahman, AA; El-Gowelli, HM; El-Mas, MM; Saad, EI, 2011) |
| "SOD-mediated vasorelaxation may contribute to the chronic antihypertensive effect and/or the improvement in insulin sensitivity following pioglitazone treatment." | 3.76 | Pioglitazone improves superoxide dismutase mediated vascular reactivity in the obese Zucker rat. ( Bryer-Ash, M; Dorafshar, AH; Khoe, M; Lyon, C; Moodley, K, 2010) |
| "Long-term administration of pioglitazone attenuated left ventricular hypertrophy and fibrosis as well as inhibited phosphorylation of mammalian target of rapamycin and p70S6 kinase in the heart of hypertensive rats." | 3.74 | Pioglitazone attenuates cardiac hypertrophy in rats with salt-sensitive hypertension: role of activation of AMP-activated protein kinase and inhibition of Akt. ( Cheng, XW; Kato, MF; Koike, Y; Miyachi, M; Murate, T; Murohara, T; Nagata, K; Nishizawa, T; Noda, A; Obata, K; Shibata, R; Tsuboi, K; Yamada, T; Yazawa, H; Yokota, M, 2008) |
| "The present study demonstrated that pioglitazone can restore the nocturnal BP declines in parallel to reductions in the HOMA index, suggesting that insulin resistance may play an important role in the genesis of circadian BP rhythms." | 3.74 | Pioglitazone shift circadian rhythm of blood pressure from non-dipper to dipper type in type 2 diabetes mellitus. ( Anan, F; Eshima, N; Fukunaga, N; Iwao, T; Kaneda, K; Masaki, T; Okada, K; Saikawa, T; Teshima, Y; Umeno, Y; Wakasugi, K; Yonemochi, H; Yoshimatsu, H, 2007) |
| " We have studied the effects of pioglitazone and rosiglitazone on the endothelial ability to counteract vascular smooth muscle contractility in genetic hypertension." | 3.74 | Effects of pioglitazone and rosiglitazone on aortic vascular function in rat genetic hypertension. ( Llorens, S; Mendizabal, Y; Nava, E, 2007) |
| "Very recent subgroup analysis from the PROspective pioglitAzone Clinical Trial In macroVascular Events has shown that pioglitazone reduces the risk of recurrent stroke in type 2 diabetic patients." | 3.74 | Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure. ( Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Nakamura, T; Ogawa, H; Tokutomi, Y; Yamamoto, E; Yamashita, T, 2007) |
| "We examined oxidative stress and metabolic characteristics of the spontaneously hypertensive hyperlipidemic rat (SHHR) when it was fed a high-fat diet and sucrose solution (HFDS) after N(G)-nitro-L-arginine methyl ester ingestion to develop a rat model of metabolic syndrome." | 3.74 | Effects of pioglitazone on increases in visceral fat accumulation and oxidative stress in spontaneously hypertensive hyperlipidemic rats fed a high-fat diet and sucrose solution. ( Iwai, S; Kobayashi, S; Kumai, T; Oguchi, K; Okazaki, M; Saiki, R, 2007) |
| " Stroke-prone spontaneously hypertensive rats (SHRSP) were orally given pioglitazone, candesartan, or combined pioglitazone and candesartan for 4 weeks to compare their effects on cardiovascular injury." | 3.74 | Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. ( Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Nakamura, T; Ogawa, H; Tokutomi, Y; Yamamoto, E; Yamashita, T, 2008) |
| "The present results suggest that pioglitazone improves not only insulin resistance, but also the dysfunctions in vascular control regulated by adrenergic and CGRPergic nerves in the hyperinsulinaemic state." | 3.74 | Pioglitazone opposes neurogenic vascular dysfunction associated with chronic hyperinsulinaemia. ( Egawa, T; Hanafusa, N; Kawasaki, H; Mio, M; Takatori, S; Yabumae, N; Zamami, Y, 2008) |
| "The present study investigates the effect of pioglitazone treatment on blood pressure, vascular reactivity and antioxidant enzymes in L-NAME induced hypertension in normal and STZ-diabetic rats." | 3.73 | Effect of pioglitazone on L-NAME induced hypertension in diabetic rats. ( Balaraman, R; Majithiya, JB; Parmar, AN; Trivedi, CJ, 2005) |
| "We investigated the long-term effects of the thiazolidinedione PPARgamma activator pioglitazone on cardiac inflammation in stroke-prone spontaneously hypertensive rats (SHRSP), a model of malignant of hypertension." | 3.72 | Long-term effects of the PPAR gamma activator pioglitazone on cardiac inflammation in stroke-prone spontaneously hypertensive rats. ( Amiri, F; Benkirane, K; Diep, QN; Paradis, P; Schiffrin, EL, 2004) |
| " This study was undertaken to examine the in vivo effects of the thiazolidine compound pioglitazone (PIO) on carotid neointimal thickening, after endothelial injury in Wistar rats and vascular hypertrophy in stroke-prone spontaneously hypertensive rats (SHR-SP/Izm)." | 3.70 | Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy. ( Demura, H; Irie, K; Muraki, T; Naruse, K; Naruse, M; Shizume, H; Tago, K; Tanabe, A; Tanaka, M; Yoshimoto, T; Zardi, L, 1999) |
| " Pioglitazone, a thiazolidinedione derivative, sensitizes target tissues to insulin and decreases hyperglycemia and hyperinsulinemia in various insulin-resistant animals." | 3.70 | Pioglitazone attenuates basal and postprandial insulin concentrations and blood pressure in the spontaneously hypertensive rat. ( Gonzalez, R; Grinsell, JW; Lardinois, CK; Michaels, JR; Sare, JS; Starich, GH; Swislocki, A, 2000) |
| "We examined the effect of pioglitazone, a thiazolidinedione derivative that increases insulin sensitivity without increasing insulin secretion, on the development and maintenance of hypertension in sucrose-fed SHR." | 3.69 | Reduction of insulin resistance attenuates the development of hypertension in sucrose-fed SHR. ( Fujita, H; Hatta, T; Itoh, H; Kawa, T; Kiyama, M; Miki, S; Moriguchi, J; Morimoto, S; Nakagawa, M; Nakamura, K; Nakata, T; Sasaki, S; Takeda, K; Uchida, A, 1997) |
| "Pioglitazone use in combination with insulin resulted in a sustained improved glycemic control and allowed the treatment regimens to be simplified and the insulin doses reduced." | 2.75 | Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19). ( Birkeland, K; Charbonnel, B; Davidson, J; DeFronzo, R; Pirags, V; Scheen, A; Schmitz, O, 2010) |
| "Hypertension is often associated with insulin resistance, dyslipidemia and obesity, which indicate a prediabetic state and increased risk of cardiovascular disease." | 2.70 | Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. ( Badenhoop, K; Füllert, S; Haak, E; Konrad, T; Lübben, G; Rau, H; Schneider, F; Usadel, KH, 2002) |
| "Metabolic syndrome is considered as clustering of cardiovascular risk factors related to insulin resistance." | 2.44 | [Pioglitazone effects on blood pressure in patients with metabolic syndrome]. ( Kushiro, T; Takahashi, A, 2008) |
| "Overall, 7% of the US population has type 2 diabetes mellitus (T2DM), and among people aged 60 years or older, approximately 20% have T2DM, representing a significant health burden in this age group." | 2.44 | Initiating insulin in patients with type 2 diabetes. ( Aoki, TJ; White, RD, 2007) |
| "Pioglitazone was given orally [10mg/kg/day] for 28 days and adiponectin intraperitoneally [2." | 1.56 | Renoprotective and haemodynamic effects of adiponectin and peroxisome proliferator-activated receptor agonist, pioglitazone, in renal vasculature of diabetic Spontaneously hypertensive rats. ( Abdul Sattar, M; Afzal, S; Eseyin, OA; Johns, EJ, 2020) |
| "It is the compensatory hyperinsulinemia rather than insulin resistance per se that causes blood pressure elevation." | 1.56 | Hyperinsulinemia rather than insulin resistance itself induces blood pressure elevation in high fat diet-fed rats. ( Chen, Y; Li, G; Pan, L; Shen, X; Tian, Y; Wang, H, 2020) |
| "Pioglitazone was also associated with reduced recurrent IS in patients who also used telmisartan (p for interaction = 0." | 1.56 | Pioglitazone and PPAR-γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study. ( Lee, TH; Li, YR; Lin, YS; Liu, CH; Sung, PS; Wei, YC, 2020) |
| "Pioglitazone treatment in adult BHR caused no detectable changes in antioxidant and detoxificant responses." | 1.51 | Age-dependent effect of PPARγ agonist pioglitazone on kidney signaling in borderline hypertensive rats. ( Dovinova, I; Grešová, L; Kvandova, M; Kvasnicka, P, 2019) |
| "The prevalence of hypertension is very common amongst the diabetic patients and is reported as the major cause of mortality in diabetes." | 1.46 | Assessment of preclinical pharmacokinetics and acute toxicity of pioglitazone and telmisartan combination. ( Chatterjee, B; Pal, TK; Sengupta, P, 2017) |
| "Biochemical markers of NAFLD worsened over time." | 1.40 | Resistant nonalcoholic fatty liver disease amelioration with rosuvastatin and pioglitazone combination therapy in a patient with metabolic syndrome. ( Black, CA; Fleming, JW; Malinowski, SS; Miller, KH; Riche, DM; Wofford, MR, 2014) |
| "Pioglitazone treatment (2." | 1.38 | Reduction of renal lipid content and proteinuria by a PPAR-γ agonist in a rat model of angiotensin II-induced hypertension. ( Hongo, M; Ishizaka, N; Nagai, R; Saito, K; Sakamoto, A, 2012) |
| "Pioglitazone improved endothelial function in hypertensive patients with IGT through an increase in nitric oxide bioavailability by, in part, a decrease in oxidative stress." | 1.36 | Pioglitazone improves endothelium-dependent vasodilation in hypertensive patients with impaired glucose tolerance in part through a decrease in oxidative stress. ( Chayama, K; Fujii, Y; Fujimura, N; Goto, C; Hata, T; Hidaka, T; Higashi, Y; Idei, N; Kihara, Y; Nakagawa, K; Soga, J, 2010) |
| "Rosiglitazone treatment curtailed the post-ischemic expression of the pro-inflammatory genes interleukin-1beta, interleukin-6, macrophage inflammatory protein-1alpha, monocyte chemoattractant protein-1, cyclooxygenase-2, inducible nitric oxide synthase, early growth response-1, CCAAT/enhancer binding protein-beta and nuclear factor-kappa B, and increased the expression of the anti-oxidant enzymes catalase and copper/zinc-superoxide dismutase." | 1.34 | Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. ( Bowen, KK; Feinstein, DL; Kapadia, R; Liang, J; Satriotomo, I; Tureyen, K; Vemuganti, R, 2007) |
| "Pioglitazone treatment increased PPARgamma expression and activity in OP rats, suggesting a possible direct ligand-related effect of pioglitazone." | 1.32 | Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity. ( Dobrian, AD; Khraibi, AA; Prewitt, RL; Schriver, SD, 2004) |
| "Treatment with pioglitazone significantly improved glucose and lipid metabolism." | 1.30 | Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. ( Aikawa, E; Demura, H; Demura, R; Imaki, T; Naruse, K; Naruse, M; Nishikawa, M; Seki, T; Tanabe, A; Yoshimoto, T, 1997) |
| "When pioglitazone was administered to the rats at a dose of 10 mg/kg/day for 4 weeks from 12 weeks of age, plasma triglyceride and insulin levels and systolic blood pressure decreased, and blood glucose reduction in response to insulin was normalized." | 1.30 | Effect of an insulin sensitizer, pioglitazone, on hypertension in fructose-drinking rats. ( Ikeda, H; Nomura, C; Odaka, H; Suzuki, M, 1997) |
| "Hypertension is frequently associated with insulin resistance." | 1.29 | Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. ( Boegehold, MA; Dubey, RK; Kotchen, TA; Reddy, SR; Zhang, HY, 1993) |
| "Pioglitazone treatment prevented the development of hypertension and reduced plasma insulin concentration by 70% and 37% in rats fed a high-fat or glucose diet, respectively (P < ." | 1.29 | Pioglitazone attenuates diet-induced hypertension in rats. ( DeGrange, LM; Kaufman, LN; Peterson, MM, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (7.61) | 18.2507 |
| 2000's | 43 (46.74) | 29.6817 |
| 2010's | 34 (36.96) | 24.3611 |
| 2020's | 8 (8.70) | 2.80 |
| Authors | Studies |
|---|---|
| Willson, TM | 1 |
| Brown, PJ | 1 |
| Sternbach, DD | 1 |
| Henke, BR | 1 |
| Blöcher, R | 1 |
| Lamers, C | 1 |
| Wittmann, SK | 1 |
| Merk, D | 1 |
| Hartmann, M | 1 |
| Weizel, L | 1 |
| Diehl, O | 1 |
| Brüggerhoff, A | 1 |
| Boß, M | 1 |
| Kaiser, A | 1 |
| Schader, T | 1 |
| Göbel, T | 1 |
| Grundmann, M | 1 |
| Angioni, C | 1 |
| Heering, J | 1 |
| Geisslinger, G | 1 |
| Wurglics, M | 1 |
| Kostenis, E | 1 |
| Brüne, B | 1 |
| Steinhilber, D | 1 |
| Schubert-Zsilavecz, M | 1 |
| Kahnt, AS | 1 |
| Proschak, E | 1 |
| Soliman, E | 1 |
| Behairy, SF | 1 |
| El-Maraghy, NN | 1 |
| Elshazly, SM | 1 |
| Liu, CH | 1 |
| Lee, TH | 1 |
| Lin, YS | 1 |
| Sung, PS | 1 |
| Wei, YC | 1 |
| Li, YR | 1 |
| Carboni, E | 2 |
| Carta, AR | 1 |
| Wang, H | 2 |
| Tian, Y | 1 |
| Chen, Y | 1 |
| Shen, X | 1 |
| Pan, L | 1 |
| Li, G | 1 |
| Hegazy, M | 1 |
| El-Shafey, M | 1 |
| Abulsoud, AI | 1 |
| Elsadek, BEM | 1 |
| Abd Elaziz, AI | 1 |
| Salama, SA | 1 |
| Spence, JD | 1 |
| Afzal, S | 2 |
| Abdul Sattar, M | 1 |
| Johns, EJ | 2 |
| Eseyin, OA | 2 |
| Ramkanth, S | 1 |
| Anitha, P | 1 |
| Gayathri, R | 1 |
| Mohan, S | 1 |
| Babu, D | 1 |
| Lin, HL | 1 |
| Cheng, PW | 1 |
| Tu, YC | 1 |
| Yeh, BC | 1 |
| Wu, BN | 1 |
| Shen, KP | 1 |
| Ueki, N | 1 |
| Kanasaki, K | 1 |
| Kanasaki, M | 1 |
| Takeda, S | 1 |
| Koya, D | 1 |
| Yamada, T | 2 |
| Hiraoka, E | 1 |
| Miyazaki, T | 1 |
| Sato, J | 1 |
| Ban, N | 1 |
| Sengupta, P | 1 |
| Chatterjee, B | 1 |
| Pal, TK | 1 |
| Sattar, MA | 1 |
| Akhtar, S | 1 |
| Binti Abdullah, NA | 1 |
| Abdulla, MH | 1 |
| Kvandova, M | 2 |
| Barancik, M | 1 |
| Balis, P | 1 |
| Puzserova, A | 1 |
| Majzunova, M | 1 |
| Dovinova, I | 3 |
| Grešová, L | 1 |
| Kvasnicka, P | 1 |
| Suzuki, H | 1 |
| Sakamoto, M | 1 |
| Hayashi, T | 1 |
| Iuchi, H | 1 |
| Ohashi, K | 1 |
| Isaka, T | 1 |
| Sakamoto, N | 1 |
| Kayama, Y | 1 |
| Tojo, K | 1 |
| Yoshimura, M | 2 |
| Utsunomiya, K | 1 |
| Riche, DM | 1 |
| Fleming, JW | 1 |
| Malinowski, SS | 1 |
| Black, CA | 1 |
| Miller, KH | 1 |
| Wofford, MR | 1 |
| Yoshii, H | 1 |
| Onuma, T | 1 |
| Yamazaki, T | 1 |
| Watada, H | 1 |
| Matsuhisa, M | 1 |
| Matsumoto, M | 1 |
| Kitagawa, K | 1 |
| Kitakaze, M | 1 |
| Yamasaki, Y | 1 |
| Kawamori, R | 1 |
| Campia, U | 2 |
| Matuskey, LA | 2 |
| Tesauro, M | 1 |
| Cardillo, C | 1 |
| Panza, JA | 2 |
| Straznicky, NE | 1 |
| Grima, MT | 1 |
| Sari, CI | 1 |
| Eikelis, N | 1 |
| Lambert, GW | 1 |
| Nestel, PJ | 1 |
| Karapanagiotidis, S | 1 |
| Wong, C | 1 |
| Richards, K | 1 |
| Marusic, P | 1 |
| Dixon, JB | 1 |
| Schlaich, MP | 1 |
| Lambert, EA | 1 |
| Wu, KL | 1 |
| Chao, YM | 1 |
| Tsay, SJ | 1 |
| Chen, CH | 1 |
| Chan, SH | 1 |
| Chan, JY | 1 |
| Hasan, DM | 1 |
| Starke, RM | 1 |
| Gu, H | 1 |
| Wilson, K | 1 |
| Chu, Y | 1 |
| Chalouhi, N | 1 |
| Heistad, DD | 1 |
| Faraci, FM | 1 |
| Sigmund, CD | 1 |
| Yu, Y | 1 |
| Xue, BJ | 1 |
| Wei, SG | 1 |
| Zhang, ZH | 1 |
| Beltz, TG | 1 |
| Guo, F | 1 |
| Johnson, AK | 1 |
| Felder, RB | 1 |
| Sakamoto, A | 3 |
| Higashikuni, Y | 1 |
| Hongo, M | 3 |
| Imai, Y | 1 |
| Koike, K | 1 |
| Nagai, R | 3 |
| Komuro, I | 1 |
| Ishizaka, N | 3 |
| Kamimura, D | 1 |
| Uchino, K | 1 |
| Ishigami, T | 1 |
| Hall, ME | 1 |
| Umemura, S | 1 |
| Koh, KK | 1 |
| Quon, MJ | 1 |
| Kato, MF | 1 |
| Shibata, R | 1 |
| Obata, K | 1 |
| Miyachi, M | 1 |
| Yazawa, H | 1 |
| Tsuboi, K | 1 |
| Nishizawa, T | 1 |
| Noda, A | 1 |
| Cheng, XW | 1 |
| Murate, T | 1 |
| Koike, Y | 1 |
| Murohara, T | 1 |
| Yokota, M | 1 |
| Nagata, K | 1 |
| Imanishi, T | 1 |
| Kobayashi, K | 1 |
| Kuroi, A | 1 |
| Ikejima, H | 1 |
| Akasaka, T | 1 |
| Aoki, TJ | 1 |
| White, RD | 1 |
| Takahashi, A | 1 |
| Kushiro, T | 1 |
| Abe, M | 1 |
| Okada, K | 2 |
| Kikuchi, F | 1 |
| Matsumoto, K | 1 |
| Miyata, T | 1 |
| van Ypersele de Strihou, C | 1 |
| Schneider, F | 2 |
| Vossler, S | 1 |
| Franke, S | 1 |
| Bär, F | 1 |
| Konrad, T | 3 |
| Hidaka, T | 1 |
| Nakagawa, K | 1 |
| Goto, C | 1 |
| Soga, J | 1 |
| Fujii, Y | 1 |
| Hata, T | 1 |
| Idei, N | 1 |
| Fujimura, N | 1 |
| Chayama, K | 1 |
| Kihara, Y | 1 |
| Higashi, Y | 1 |
| Charbonnel, B | 1 |
| DeFronzo, R | 1 |
| Davidson, J | 1 |
| Schmitz, O | 1 |
| Birkeland, K | 1 |
| Pirags, V | 1 |
| Scheen, A | 1 |
| Dorafshar, AH | 1 |
| Moodley, K | 1 |
| Khoe, M | 1 |
| Lyon, C | 1 |
| Bryer-Ash, M | 1 |
| Zanchi, A | 1 |
| Maillard, M | 1 |
| Jornayvaz, FR | 1 |
| Vinciguerra, M | 1 |
| Deleaval, P | 1 |
| Nussberger, J | 1 |
| Burnier, M | 1 |
| Pechere-Bertschi, A | 1 |
| El-Mas, MM | 1 |
| El-Gowelli, HM | 1 |
| Abd-Elrahman, KS | 1 |
| Saad, EI | 1 |
| Abdel-Galil, AG | 1 |
| Abdel-Rahman, AA | 1 |
| Zhang, X | 1 |
| Zhang, R | 1 |
| Raab, S | 1 |
| Zheng, W | 1 |
| Wang, J | 1 |
| Liu, N | 1 |
| Zhu, T | 1 |
| Xue, L | 1 |
| Song, Z | 1 |
| Mao, J | 1 |
| Li, K | 1 |
| Zhang, H | 1 |
| Zhang, Y | 1 |
| Han, C | 1 |
| Ding, Y | 1 |
| Hou, N | 1 |
| Liu, Y | 1 |
| Shang, S | 1 |
| Li, C | 1 |
| Sebokova, E | 1 |
| Cheng, H | 1 |
| Huang, PL | 1 |
| Takai, S | 1 |
| Jin, D | 1 |
| Miyazaki, M | 1 |
| Morikawa, A | 1 |
| Ishizeki, K | 1 |
| Iwashima, Y | 2 |
| Yokoyama, H | 1 |
| Muto, E | 1 |
| Oshima, E | 1 |
| Sekiguchi, M | 1 |
| Miura, T | 1 |
| Itoh, H | 2 |
| Haneda, M | 1 |
| El-Bassossy, HM | 1 |
| Fahmy, A | 1 |
| Badawy, D | 1 |
| Mendizábal, Y | 2 |
| Llorens, S | 2 |
| Nava, E | 2 |
| Kaku, K | 1 |
| Enya, K | 1 |
| Sugiura, K | 1 |
| Totsuka, N | 1 |
| Hernanz, R | 1 |
| Martín, Á | 1 |
| Pérez-Girón, JV | 1 |
| Palacios, R | 1 |
| Briones, AM | 1 |
| Miguel, M | 1 |
| Salaices, M | 1 |
| Alonso, MJ | 1 |
| Furuta, K | 1 |
| Saito, K | 2 |
| Foulquier, S | 1 |
| Dupuis, F | 1 |
| Perrin-Sarrado, C | 1 |
| Gatè, KM | 1 |
| Leroy, P | 1 |
| Liminana, P | 1 |
| Atkinson, J | 1 |
| Capdeville-Atkinson, C | 1 |
| Lartaud, I | 1 |
| Kashiwagi, Y | 1 |
| Mizuno, Y | 1 |
| Harada, E | 1 |
| Shono, M | 1 |
| Morita, S | 1 |
| Yano, M | 1 |
| Yasue, H | 1 |
| Nishimoto, Y | 1 |
| Tomida, T | 1 |
| Matsui, H | 1 |
| Ito, T | 1 |
| Okumura, K | 1 |
| Kotake, H | 1 |
| Füllert, S | 2 |
| Haak, E | 1 |
| Rau, H | 1 |
| Badenhoop, K | 1 |
| Lübben, G | 2 |
| Usadel, KH | 1 |
| Suzuki, M | 4 |
| Odaka, H | 2 |
| Winkler, K | 1 |
| Friedrich, I | 1 |
| Destani, R | 1 |
| Baumstark, MW | 1 |
| Krebs, K | 1 |
| Wieland, H | 1 |
| März, W | 1 |
| Dobrian, AD | 1 |
| Schriver, SD | 1 |
| Khraibi, AA | 1 |
| Prewitt, RL | 1 |
| Negro, R | 1 |
| Dazzi, D | 1 |
| Hassan, H | 1 |
| Pezzarossa, A | 1 |
| Wakino, S | 1 |
| Hayashi, K | 1 |
| Kanda, T | 1 |
| Tatematsu, S | 1 |
| Homma, K | 1 |
| Yoshioka, K | 1 |
| Takamatsu, I | 1 |
| Saruta, T | 1 |
| Diep, QN | 1 |
| Amiri, F | 1 |
| Benkirane, K | 1 |
| Paradis, P | 1 |
| Schiffrin, EL | 1 |
| Barbaro, D | 1 |
| Lapi, P | 1 |
| Orsini, P | 1 |
| Pasquini, C | 1 |
| Ciaccio, S | 1 |
| Horio, T | 2 |
| Suzuki, K | 2 |
| Takamisawa, I | 2 |
| Hiuge, A | 2 |
| Kamide, K | 1 |
| Takiuchi, S | 1 |
| Kihara, S | 1 |
| Funahashi, T | 1 |
| Yoshimasa, Y | 2 |
| Kawano, Y | 2 |
| Majithiya, JB | 1 |
| Parmar, AN | 1 |
| Trivedi, CJ | 1 |
| Balaraman, R | 1 |
| Ledingham, JM | 1 |
| Laverty, R | 1 |
| Qayyum, R | 1 |
| Adomaityte, J | 1 |
| El Midaoui, A | 1 |
| Wu, L | 1 |
| Wang, R | 1 |
| de Champlain, J | 1 |
| Sarafidis, PA | 1 |
| Nilsson, PM | 1 |
| Schöndorf, T | 1 |
| Forst, T | 1 |
| Hohberg, C | 1 |
| Pahler, S | 1 |
| Link, C | 2 |
| Roth, W | 1 |
| Pfützner, A | 2 |
| Takase, H | 1 |
| Nakazawa, A | 1 |
| Yamashita, S | 1 |
| Toriyama, T | 1 |
| Sato, K | 1 |
| Ueda, R | 1 |
| Dohi, Y | 1 |
| Tureyen, K | 1 |
| Kapadia, R | 1 |
| Bowen, KK | 1 |
| Satriotomo, I | 1 |
| Liang, J | 1 |
| Feinstein, DL | 1 |
| Vemuganti, R | 1 |
| Derosa, G | 1 |
| Fogari, E | 1 |
| Cicero, AF | 1 |
| D'Angelo, A | 1 |
| Ciccarelli, L | 1 |
| Piccinni, MN | 1 |
| Pricolo, F | 1 |
| Salvadeo, SA | 1 |
| Gravina, A | 1 |
| Ferrari, I | 1 |
| Fogari, R | 1 |
| de Rivas, B | 1 |
| Luque, M | 1 |
| Martell, N | 1 |
| Fernández, C | 1 |
| Fernández-Cruz, A | 1 |
| Anan, F | 1 |
| Masaki, T | 1 |
| Fukunaga, N | 1 |
| Teshima, Y | 1 |
| Iwao, T | 1 |
| Kaneda, K | 1 |
| Umeno, Y | 1 |
| Wakasugi, K | 1 |
| Yonemochi, H | 1 |
| Eshima, N | 1 |
| Saikawa, T | 1 |
| Yoshimatsu, H | 1 |
| Nakamura, T | 2 |
| Yamamoto, E | 2 |
| Kataoka, K | 2 |
| Yamashita, T | 2 |
| Tokutomi, Y | 2 |
| Dong, YF | 2 |
| Matsuba, S | 2 |
| Ogawa, H | 2 |
| Kim-Mitsuyama, S | 2 |
| Saiki, R | 1 |
| Okazaki, M | 1 |
| Iwai, S | 1 |
| Kumai, T | 1 |
| Kobayashi, S | 1 |
| Oguchi, K | 1 |
| Shinzato, T | 2 |
| Ohya, Y | 2 |
| Nakamoto, M | 2 |
| Ishida, A | 1 |
| Takishita, S | 2 |
| Goldberg, RB | 1 |
| Holman, R | 1 |
| Drucker, DJ | 1 |
| Takatori, S | 1 |
| Zamami, Y | 1 |
| Yabumae, N | 1 |
| Hanafusa, N | 1 |
| Mio, M | 1 |
| Egawa, T | 1 |
| Kawasaki, H | 1 |
| Barac, A | 1 |
| Lu, L | 1 |
| Mano, R | 1 |
| Yamazato, M | 1 |
| Sakima, A | 1 |
| Kaufman, LN | 1 |
| Peterson, MM | 1 |
| DeGrange, LM | 1 |
| Dubey, RK | 1 |
| Zhang, HY | 1 |
| Reddy, SR | 1 |
| Boegehold, MA | 1 |
| Kotchen, TA | 1 |
| Yoshimoto, T | 3 |
| Naruse, M | 3 |
| Nishikawa, M | 1 |
| Naruse, K | 2 |
| Tanabe, A | 3 |
| Seki, T | 1 |
| Imaki, T | 1 |
| Demura, R | 1 |
| Aikawa, E | 1 |
| Demura, H | 2 |
| Uchida, A | 1 |
| Nakata, T | 1 |
| Hatta, T | 1 |
| Kiyama, M | 1 |
| Kawa, T | 1 |
| Morimoto, S | 1 |
| Miki, S | 1 |
| Moriguchi, J | 1 |
| Nakamura, K | 1 |
| Fujita, H | 1 |
| Sasaki, S | 1 |
| Takeda, K | 1 |
| Nakagawa, M | 1 |
| Nomura, C | 1 |
| Ikeda, H | 1 |
| Verma, S | 1 |
| Bhanot, S | 1 |
| Arikawa, E | 1 |
| Yao, L | 1 |
| McNeill, JH | 1 |
| Shizume, H | 1 |
| Tanaka, M | 1 |
| Tago, K | 2 |
| Irie, K | 1 |
| Muraki, T | 1 |
| Zardi, L | 1 |
| Grinsell, JW | 1 |
| Lardinois, CK | 1 |
| Swislocki, A | 1 |
| Gonzalez, R | 1 |
| Sare, JS | 1 |
| Michaels, JR | 1 |
| Starich, GH | 1 |
| Takagi, S | 1 |
| Takano, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Mechanisms of Sympathetic Overactivity in the Metabolic Syndrome: Effects of Reversing Insulin Resistance by Drug Treatment[NCT00408850] | Phase 3 | 44 participants (Anticipated) | Interventional | 2008-11-30 | Recruiting | ||
| PROspective PioglitAzone Clinical Trial In MacroVascular Events: A Macrovascular Outcome Study in Type 2 Diabetic Patients Comparing Pioglitazone With Placebo in Addition to Existing Therapy[NCT00174993] | Phase 3 | 4,373 participants (Actual) | Interventional | 2001-05-31 | Completed | ||
| Effects of the PPAR-gamma Agonist Pioglitazone on Renal and Hormonal Responses to Salt in Diabetic and Hypertensive Subjects[NCT01090752] | Phase 4 | 16 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| The Effect of Ezetimibe 10 mg, Simvastatin 20 mg and the Combination of Simvastatin 20 mg Plus 10 mg Ezetimibe on Low Density Lipoprotein (LDL)-Subfractions in Patients With Type 2 Diabetes[NCT01384058] | Phase 4 | 41 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
24 hour blood pressure measurements were performed after each treatment/diet phase (NCT01090752)
Timeframe: march 2009
| Intervention | mmHg (Mean) |
|---|---|
| Pioglitazone Low Salt/High Salt | 128 |
| Placebo Low Salt/High Salt | 129 |
At the end of each treatment diet phase, renal clearances were performed for the determination of GFR and RBF (NCT01090752)
Timeframe: 2008
| Intervention | ml/min/1.73m2 (Mean) |
|---|---|
| Pioglitazone Low Salt/High Salt | 68.0 |
| Placebo Low Salt/High Salt | 62.4 |
At the end of each treatment and diet phase, 24 urine collections were collected for the determination of sodium and lithium clearances (NCT01090752)
Timeframe: 2007
| Intervention | ml/min (Mean) |
|---|---|
| Pioglitazone Low Salt/High Salt | 1.05 |
| Placebo Low Salt/High Salt | 1.18 |
9 reviews available for pioglitazone and Hypertension
| Article | Year |
|---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligand | 2000 |
Recent advances in preventing recurrent stroke.
Topics: Aged; Blood Pressure; Diet; Endarterectomy, Carotid; Humans; Hypertension; Pioglitazone; Recurrence; | 2020 |
Initiating insulin in patients with type 2 diabetes.
Topics: Blood Glucose; Cholesterol; Comorbidity; Diabetes Mellitus, Type 2; Drug Monitoring; Drug Therapy, C | 2007 |
[Pioglitazone effects on blood pressure in patients with metabolic syndrome].
Topics: Clinical Trials as Topic; Humans; Hypertension; Hypoglycemic Agents; Insulin Resistance; Meta-Analys | 2008 |
[Syndrome X].
Topics: Animals; Bezafibrate; Biguanides; Fatty Acids, Nonesterified; Humans; Hyperglycemia; Hyperinsulinism | 2002 |
[Hypertension and insulin resistance in obese type 2 diabetic Wistar fatty rat].
Topics: Animals; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 2; Disease Models, Anima | 2003 |
A meta-analysis of the effect of thiazolidinediones on blood pressure.
Topics: Blood Pressure; Clinical Trials as Topic; Humans; Hypertension; Hypoglycemic Agents; Insulin Resista | 2006 |
The effects of thiazolidinediones on blood pressure levels - a systematic review.
Topics: Blood Pressure; Chromans; Humans; Hypertension; MEDLINE; Pioglitazone; Rosiglitazone; Thiazolidinedi | 2006 |
[Insulin-sensitizing agents and hypertension].
Topics: Animals; Chromans; Humans; Hypertension; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Thia | 2000 |
19 trials available for pioglitazone and Hypertension
| Article | Year |
|---|---|
Effects of pioglitazone on macrovascular events in patients with type 2 diabetes mellitus at high risk of stroke: the PROFIT-J study.
Topics: Aged; Aged, 80 and over; Blood Pressure; Diabetes Complications; Diabetes Mellitus, Type 2; Dyslipid | 2014 |
PPARγ activation does not affect endothelin activity in non-diabetic patients with hypertension or hypercholesterolemia.
Topics: Biomarkers; C-Reactive Protein; Cross-Over Studies; District of Columbia; Double-Blind Method; Endot | 2014 |
A randomized controlled trial of the effects of pioglitazone treatment on sympathetic nervous system activity and cardiovascular function in obese subjects with metabolic syndrome.
Topics: Blood Pressure; Diastole; Double-Blind Method; Echocardiography, Doppler; Endothelium, Vascular; Fem | 2014 |
Clinical investigation of the effects of pioglitazone on the improvement of insulin resistance and blood pressure in type 2-diabetic patients undergoing hemodialysis.
Topics: Aged; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glyc | 2008 |
Impact of insulin sensitivity treatment with pioglitazone on endothelial function in non-diabetic patients with arterial hypertension.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Brachial Arte | 2009 |
Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19).
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Dia | 2010 |
Effects of the peroxisome proliferator-activated receptor (PPAR)-gamma agonist pioglitazone on renal and hormonal responses to salt in diabetic and hypertensive individuals.
Topics: Analysis of Variance; Blood Pressure; Body Weight; Cross-Over Studies; Diabetes Mellitus, Type 2; Do | 2010 |
Pioglitazone reduces urinary albumin excretion in renin-angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti | 2011 |
Efficacy and safety of combination therapy with candesartan cilexetil and pioglitazone hydrochloride in patients with hypertension and type 2 diabetes mellitus.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diabetes Complica | 2011 |
Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study.
Topics: Apolipoproteins B; Blood Glucose; Cholesterol, HDL; Double-Blind Method; Fasting; Female; Homeostasi | 2002 |
Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study.
Topics: Arteriosclerosis; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; | 2003 |
Pioglitazone reduces blood pressure in non-dipping diabetic patients.
Topics: Antihypertensive Agents; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circa | 2004 |
Pioglitazone improves left ventricular diastolic function in patients with essential hypertension.
Topics: Adiponectin; Aged; Blood Glucose; Blood Pressure; Diastole; Echocardiography; Female; Glucose Tolera | 2005 |
Pioglitazone-induced insulin sensitization improves vascular endothelial function in nondiabetic patients with essential hypertension.
Topics: Aged; Area Under Curve; Blood Glucose; Brachial Artery; Endothelium, Vascular; Female; Humans; Hyper | 2005 |
The IRIS III study: pioglitazone improves metabolic control and blood pressure in patients with type 2 diabetes without increasing body weight.
Topics: Aged; Body Weight; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Hypoglycemic Agents; Mal | 2007 |
Pioglitazone produces rapid and persistent reduction of vascular inflammation in patients with hypertension and type 2 diabetes mellitus who are receiving angiotensin II receptor blockers.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Diabetes Mellitus, | 2007 |
Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin.
Topics: Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glyca | 2007 |
Pioglitazone decreases ambulatory blood pressure in type 2 diabetics with difficult-to-control hypertension.
Topics: Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; | 2007 |
Effects of peroxisome proliferator-activated receptor-gamma activation with pioglitazone on plasma adipokines in nondiabetic patients with either hypercholesterolemia or hypertension.
Topics: Adipokines; Adiponectin; Adult; Aged; Case-Control Studies; Cross-Over Studies; Double-Blind Method; | 2008 |
64 other studies available for pioglitazone and Hypertension
| Article | Year |
|---|---|
N-Benzylbenzamides: A Novel Merged Scaffold for Orally Available Dual Soluble Epoxide Hydrolase/Peroxisome Proliferator-Activated Receptor γ Modulators.
Topics: 3T3 Cells; Administration, Oral; Animals; Benzamides; Chlorocebus aethiops; COS Cells; Diabetes Mell | 2016 |
PPAR-γ agonist, pioglitazone, reduced oxidative and endoplasmic reticulum stress associated with L-NAME-induced hypertension in rats.
Topics: Animals; Antioxidants; Aorta; Blood Pressure; Catalase; Endoplasmic Reticulum Stress; Glutathione; H | 2019 |
Pioglitazone and PPAR-γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study.
Topics: Aged; Antihypertensive Agents; Brain Ischemia; Databases, Factual; Diabetes Mellitus, Type 2; Female | 2020 |
Can pioglitazone be potentially useful therapeutically in treating patients with COVID-19?
Topics: Anti-Inflammatory Agents; Betacoronavirus; C-Reactive Protein; Coronavirus Infections; COVID-19; COV | 2020 |
Hyperinsulinemia rather than insulin resistance itself induces blood pressure elevation in high fat diet-fed rats.
Topics: Animals; Blood Glucose; Blood Pressure; Diabetes Mellitus, Experimental; Diet, High-Fat; Hyperinsuli | 2020 |
Pioglitazone ameliorates high fat diet-induced hypertension and induces catechol o-methyl transferase expression in rats.
Topics: Animals; Antihypertensive Agents; Blood Glucose; Body Weight; Catechol O-Methyltransferase; Diet, Hi | 2020 |
Renoprotective and haemodynamic effects of adiponectin and peroxisome proliferator-activated receptor agonist, pioglitazone, in renal vasculature of diabetic Spontaneously hypertensive rats.
Topics: Adiponectin; Animals; Diabetes Mellitus, Experimental; Hemodynamics; Hypertension; Hypoglycemic Agen | 2020 |
Formulation and design optimization of nano-transferosomes using pioglitazone and eprosartan mesylate for concomitant therapy against diabetes and hypertension.
Topics: Acrylates; Animals; Diabetes Mellitus, Type 2; Drug Carriers; Drug Delivery Systems; Humans; Hyperte | 2021 |
The effectiveness comparisons of eugenosedin-A, glibenclamide and pioglitazone on diabetes mellitus induced by STZ/NA and high-fat diet in SHR.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diet, High-Fat; Glyburide; Hypertension; Hy | 2021 |
Catechol-O-Methyltransferase Deficiency Leads to Hypersensitivity of the Pressor Response Against Angiotensin II.
Topics: Angiotensin II; Animals; Catechol O-Methyltransferase; Drug Hypersensitivity; Female; Hypertension; | 2017 |
Diabetes as First Manifestation of Autoimmune Pancreatitis.
Topics: Adrenal Cortex Hormones; Aged; Autoimmune Diseases; Diabetes Complications; Diabetes Mellitus; Dysli | 2017 |
Assessment of preclinical pharmacokinetics and acute toxicity of pioglitazone and telmisartan combination.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Diabetes Mellitus; Drug Therapy, Combin | 2017 |
Effect of pioglitazone on vasopressor responses to adrenergic agonists and angiotensin II in diabetic and non-diabetic spontaneously hypertensive rats.
Topics: Adrenergic Agonists; Angiotensin II; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Hemody | 2018 |
The peroxisome proliferator-activated receptor gamma agonist pioglitazone improves nitric oxide availability, renin-angiotensin system and aberrant redox regulation in the kidney of pre-hypertensive rats.
Topics: Animals; Blood Pressure; Catalase; Gene Expression Regulation; Hypertension; Hypoglycemic Agents; Ki | 2018 |
Age-dependent effect of PPARγ agonist pioglitazone on kidney signaling in borderline hypertensive rats.
Topics: Aging; Animals; Hypertension; Kidney; Pioglitazone; PPAR gamma; Rats | 2019 |
Effects of co-administration of candesartan with pioglitazone on inflammatory parameters in hypertensive patients with type 2 diabetes mellitus: a preliminary report.
Topics: Adiponectin; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2013 |
Resistant nonalcoholic fatty liver disease amelioration with rosuvastatin and pioglitazone combination therapy in a patient with metabolic syndrome.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Diabetes Mellitus, Type 2; Drug Resistance; Drug | 2014 |
Role of nitric oxide synthase uncoupling at rostral ventrolateral medulla in redox-sensitive hypertension associated with metabolic syndrome.
Topics: Animals; Blood Pressure; Blotting, Western; Cytoplasmic Dyneins; Diet, High-Fat; Hypertension; Hypog | 2014 |
Smooth Muscle Peroxisome Proliferator-Activated Receptor γ Plays a Critical Role in Formation and Rupture of Cerebral Aneurysms in Mice In Vivo.
Topics: Aneurysm, Ruptured; Angiotensin II; Anilides; Animals; Cerebral Arteries; Endothelium, Vascular; Gen | 2015 |
Activation of central PPAR-γ attenuates angiotensin II-induced hypertension.
Topics: Angiotensin II; Anilides; Animals; Blood Pressure; Brain; Disease Models, Animal; Hypertension; Infu | 2015 |
Pioglitazone Reduces Vascular Lipid Accumulation in Angiotensin II-Induced Hypertensive Rat.
Topics: AMP-Activated Protein Kinases; Angiotensin II; Animals; Aorta; Hypertension; Immunohistochemistry; L | 2015 |
Activation of Peroxisome Proliferator-activated Receptor γ Prevents Development of Heart Failure With Preserved Ejection Fraction; Inhibition of Wnt-β-catenin Signaling as a Possible Mechanism.
Topics: Animals; beta Catenin; Collagen Type I; Disease Models, Animal; Disease Progression; Fibrosis; Heart | 2016 |
Combination therapy for treatment or prevention of atherosclerosis.
Topics: Atherosclerosis; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combin | 2008 |
Pioglitazone attenuates cardiac hypertrophy in rats with salt-sensitive hypertension: role of activation of AMP-activated protein kinase and inhibition of Akt.
Topics: Adiponectin; AMP-Activated Protein Kinases; Animals; Atrial Natriuretic Factor; Collagen; Echocardio | 2008 |
Pioglitazone inhibits angiotensin II-induced senescence of endothelial progenitor cell.
Topics: Angiotensin II; Cells, Cultured; Cellular Senescence; Drug Interactions; Gene Expression; Hematopoie | 2008 |
Translation of basic science into clinical medicine: novel targets for diabetic nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biomedical Research; Clinical Medicine; Diabetic N | 2009 |
Pioglitazone improves endothelium-dependent vasodilation in hypertensive patients with impaired glucose tolerance in part through a decrease in oxidative stress.
Topics: Acetylcholine; Aged; Amlodipine; Case-Control Studies; Endothelium, Vascular; Female; Glucose; Gluco | 2010 |
Pioglitazone improves superoxide dismutase mediated vascular reactivity in the obese Zucker rat.
Topics: Acetylcholine; Animals; Aorta; Blood Pressure; Glucose Tolerance Test; Hypertension; Hypoglycemic Ag | 2010 |
Pioglitazone abrogates cyclosporine-evoked hypertension via rectifying abnormalities in vascular endothelial function.
Topics: Animals; Antioxidants; Aorta; Cyclosporine; Endothelium, Vascular; Hypertension; Hypoglycemic Agents | 2011 |
Rhesus macaques develop metabolic syndrome with reversible vascular dysfunction responsive to pioglitazone.
Topics: Animals; Blood Vessels; Disease Models, Animal; Disease Progression; Dyslipidemias; Hyperinsulinism; | 2011 |
Irbesartan prevents metabolic syndrome in rats via activation of peroxisome proliferator-activated receptor γ.
Topics: Adiponectin; Adipose Tissue; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Bip | 2011 |
Cinnamaldehyde protects from the hypertension associated with diabetes.
Topics: Acetylcholinesterase; Acrolein; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Cal | 2011 |
Effects of pioglitazone and rosiglitazone on vascular function of mesenteric resistance arteries in rat genetic hypertension.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Acetylcholine; Animals; Blood Pr | 2011 |
Pioglitazone treatment increases COX-2-derived prostacyclin production and reduces oxidative stress in hypertensive rats: role in vascular function.
Topics: Animals; Antihypertensive Agents; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Epoprostenol; Gene Ex | 2012 |
Pioglitazone ameliorates systolic and diastolic cardiac dysfunction in rat model of angiotensin II-induced hypertension.
Topics: Angiotensin II; Animals; Blood Pressure; Diastole; Disease Models, Animal; Heart Diseases; Hypertens | 2013 |
Reduction of renal lipid content and proteinuria by a PPAR-γ agonist in a rat model of angiotensin II-induced hypertension.
Topics: Angiotensin II; Animals; Disease Models, Animal; Ferritins; Gene Expression Regulation; Heme Oxygena | 2012 |
Differential effects of short-term treatment with two AT1 receptor blockers on diameter of pial arterioles in SHR.
Topics: Angiotensin Receptor Antagonists; Animals; Arterioles; Benzimidazoles; Benzoates; Biphenyl Compounds | 2012 |
Suppression of primary aldosteronism and resistant hypertension by the peroxisome proliferator-activated receptor gamma agonist pioglitazone.
Topics: Aldosterone; Blood Pressure; Comorbidity; Humans; Hyperaldosteronism; Hypertension; Male; Middle Age | 2013 |
Decrease in renal medullary endothelial nitric oxide synthase of fructose-fed, salt-sensitive hypertensive rats.
Topics: Animals; Aorta; Blood Pressure; Dietary Sucrose; Fructose; Hypertension; Hypoglycemic Agents; Kidney | 2002 |
Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Diet; Hypertension; Insulin; Kidney; Male; NADPH O | 2004 |
Peroxisome proliferator-activated receptor gamma ligands inhibit Rho/Rho kinase pathway by inducing protein tyrosine phosphatase SHP-2.
Topics: Angiotensin II; Animals; Blood Pressure; Cell Cycle Proteins; Cells, Cultured; Chromans; Hypertensio | 2004 |
Long-term effects of the PPAR gamma activator pioglitazone on cardiac inflammation in stroke-prone spontaneously hypertensive rats.
Topics: Animals; Hypertension; Hypertrophy, Left Ventricular; Male; Myocarditis; Pioglitazone; PPAR gamma; R | 2004 |
Pioglitazone treatment in Cushing's disease.
Topics: Adrenocorticotropic Hormone; Aged; Comorbidity; Diabetes Mellitus; Female; Humans; Hydrocortisone; H | 2005 |
Effect of pioglitazone on L-NAME induced hypertension in diabetic rats.
Topics: Animals; Aorta, Thoracic; Blood Glucose; Blood Pressure; Body Weight; Catalase; Diabetes Mellitus, E | 2005 |
Effects of glitazones on blood pressure and vascular structure in mesenteric resistance arteries and basilar artery from genetically hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Basilar Artery; Blood Pressure; Disease Models, An | 2005 |
Modulation of cardiac and aortic peroxisome proliferator-activated receptor-gamma expression by oxidative stress in chronically glucose-fed rats.
Topics: Animals; Antioxidants; Aorta; Blood Pressure; Cells, Cultured; Gene Expression Regulation; Glucose; | 2006 |
Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents.
Topics: Anilides; Animals; Cerebral Infarction; Chemotaxis, Leukocyte; Cytokines; Diabetes Mellitus, Type 2; | 2007 |
Pioglitazone shift circadian rhythm of blood pressure from non-dipper to dipper type in type 2 diabetes mellitus.
Topics: Antihypertensive Agents; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circa | 2007 |
Effects of pioglitazone and rosiglitazone on aortic vascular function in rat genetic hypertension.
Topics: Acetylcholine; Animals; Aorta; Dose-Response Relationship, Drug; Endothelium, Vascular; Hypertension | 2007 |
Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure.
Topics: Animals; Blood Glucose; Blood Pressure; Cerebral Arteries; Cytokines; Diabetes Complications; Diseas | 2007 |
Effects of pioglitazone on increases in visceral fat accumulation and oxidative stress in spontaneously hypertensive hyperlipidemic rats fed a high-fat diet and sucrose solution.
Topics: Animals; Catalase; Dietary Fats; Disease Models, Animal; Fatty Acids, Nonesterified; Female; Glutath | 2007 |
Beneficial effects of pioglitazone on left ventricular hypertrophy in genetically hypertensive rats.
Topics: Animals; Blood Glucose; Blood Pressure; Collagen Type I; Collagen Type III; Connective Tissue Growth | 2007 |
Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressur | 2008 |
Clinical decisions. Management of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Gl | 2008 |
Pioglitazone opposes neurogenic vascular dysfunction associated with chronic hyperinsulinaemia.
Topics: Administration, Oral; Angiotensin II; Animals; Blood Glucose; Blood Pressure; Chronic Disease; Disea | 2008 |
Pioglitazone, a thiazolidinedione derivative, attenuates left ventricular hypertrophy and fibrosis in salt-sensitive hypertension.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Fibrosis; Hypertension; Hypertrophy, Lef | 2008 |
Pioglitazone attenuates diet-induced hypertension in rats.
Topics: Animals; Blood Glucose; Blood Pressure; Diet; Dietary Carbohydrates; Dietary Fats; Hypertension; Ins | 1995 |
Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats.
Topics: Animals; Arterioles; Blood Pressure; Cell Division; Epidermal Growth Factor; Hypertension; Hypoglyce | 1993 |
Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats.
Topics: Animals; Aorta; Arteriosclerosis; Blood Glucose; Blood Pressure; Cholesterol; Diabetes Mellitus; Dia | 1997 |
Reduction of insulin resistance attenuates the development of hypertension in sucrose-fed SHR.
Topics: Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Captopril; Catecholamines; Dietary | 1997 |
Effect of an insulin sensitizer, pioglitazone, on hypertension in fructose-drinking rats.
Topics: Animals; Blood Glucose; Blood Pressure; Disease Models, Animal; Drinking; Fructose; Hypertension; Hy | 1997 |
Direct vasodepressor effects of pioglitazone in spontaneously hypertensive rats.
Topics: Animals; Arginine Vasopressin; Drug Evaluation, Preclinical; Hyperinsulinism; Hypertension; Hypoglyc | 1998 |
Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy.
Topics: Animals; Aorta, Abdominal; Arteriosclerosis; Bromodeoxyuridine; Carotid Arteries; Cell Division; DNA | 1999 |
Pioglitazone attenuates basal and postprandial insulin concentrations and blood pressure in the spontaneously hypertensive rat.
Topics: Animals; Area Under Curve; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Gl | 2000 |